Pharmaceutical Contract Development and Manufacturing Market Major Manufacturers, Trends, Demand, Analysis and Forecasts to 2026

Pharmaceutical Contract Development and Manufacturing Market Major Manufacturers, Trends, Demand, Analysis and Forecasts to 2026

Pharmaceutical Contract Development and Manufacturing Market Overview:

The Pharmaceutical Contract Development and Manufacturing Market is projected to reach USD 171.3 billion by 2026 from USD 120.6 billion in 2021, at a CAGR of 7.3% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

This study involved four major activities in estimating the current size of the pharmaceutical contract development and manufacturing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Request For Sample: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=201524381 

COVID-19 impact on the pharmaceutical contract development and manufacturing market

Due to the Covid-19 pandemic, companies have scaled up R&D and manufacturing efforts to develop and distribute vaccines and drugs against the SARS-CoV-2 virus. Vaccine-related research activities in pharmaceutical & biotechnological companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. To expedite the R&D and manufacturing process, many pharmaceutical and biotechnology companies teamed up with CROs and CDMOs through long-term agreements, partnerships, and collaborations across the globe.


Download PDF: 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=201524381 

Market Segmentation:

Pharmaceutical Contract Development and Manufacturing Market, by Service

Pharmaceutical Manufacturing Services

Pharmaceutical API Manufacturing Services

Pharmaceutical FDF Manufacturing Services

Parenteral/injectable manufacturing services

Tablet manufacturing services

Capsule manufacturing services

Oral liquid manufacturing services

Semi-solid manufacturing services

Other formulations manufacturing services

Drug Development Services

Biologics Manufacturing Services

Biologics API manufacturing services

Biologics FDF manufacturing services

Pharmaceutical Contract Development and Manufacturing Market, by End User

Big Pharmaceutical Companies

Small & Medium-Sized Pharmaceutical Companies

Generic Pharmaceutical Companies

Other End Users

Detailed Information:

https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-contract-manufacturing-market-201524381.html 

Key Players:

Key players in the pharmaceutical contract development and manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), and Siegfried Holding AG (Switzerland)

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com